Research

Hormonal

In individuals with type 2 diabetes and obesity, treatment with glucagon-like peptide-1 receptor agonists (GLP-1RA) does not increase the risk of suicidal ideation or self-injury (SIS) compared to sodium-glucose cotransporter 2 inhibitors (SGLT-2i).

If you have type 2 diabetes and obesity, current evidence suggests that GLP-1RA medications do not increase your risk of suicidal thoughts or self-harm compared to other common diabetes drugs like SGLT-2 inhibitors. While regulators are reviewing safety data based on early reports, this large study found no such link. However, because these events are rare, the possibility of a small increased risk cannot be completely excluded, so monitoring your mental health remains important.

GoodRefutesMEDIUM confidence
Our findings do not support an increased risk of SIS when taking GLP-1RA in individuals with type 2 diabetes and obesity
Isabel Hurtado et al. · Diabetologia · 2024

Why this rating

High-quality observational study using a large population-based database, propensity weighting, and active comparator design, though limited by the rarity of the outcome.

Source

Association of glucagon-like peptide-1 receptor agonists with suicidal ideation and self-injury in individuals with diabetes and obesity: a propensity-weighted, population-based cohort study

Isabel Hurtado et al. · Diabetologia · 2024

DOI 10.1007/s00125-024-06243-z

cohort · n=14667Cited 36×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →